Richard Kovacs, MD
Cardiovascular Disease · Indianapolis, INNPI 1447215777
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $132,261 of the $136,405 with a category attached, or 97.0%. 10 manufacturers reported payments, led by Eli Lilly at 42.5% of the total. Reporting peaked in 2024 at $71,940 and has fallen 71.1% since, to $20,772 in 2025. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $1726.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$58K
- Jazz Pharmaceuticals Inc.$26K
- GSK$16K
- Cook Research Incorporated$13K
- Pfizer$11K
- E.r. Squibb & Sons, L.L.C.$7K
- plus $6K from 4 others
Across 11 payments — averaging $18,854 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$198K
- Ipsen Innovation$6K
- Siemens Medical Solutions USA, Inc.$4K
- Ipsen Biopharmaceuticals, Inc$350
What the payments were for
- Consulting fees$132,26197%
- Grants$1,7861%
- Travel & lodging$1,7091%
- Food & beverage$6490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 7 | $58,025 |
| Jazz Pharmaceuticals Inc. | 23 | $25,872 |
| GSK | 8 | $15,750 |
| Cook Research Incorporated | 23 | $12,926 |
| Pfizer | 5 | $11,021 |
| E.r. Squibb & Sons, L.L.C. | 1 | $6,500 |
| Axsome Therapeutics, Inc. | 3 | $6,000 |
| Medtronic | 7 | $204 |
| Novartis | 1 | $96 |
| Antares Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$136,405 in reported general payments places this provider in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 149 | $156,814 |
| EntrestoSacubitril/Valsartan | 25 | $32,991 |
| JardianceEmpagliflozin | 22 | $24,766 |
| Repatha SureclickEvolocumab | 21 | $18,752 |
| XareltoRivaroxaban | 14 | $12,164 |
| Praluent PenAlirocumab | 11 | $7,247 |
| Metoprolol Succinate | 136 | $2,458 |
| Atorvastatin Calcium | 162 | $2,314 |
| Potassium Chloride | 29 | $1,420 |
| Torsemide | 41 | $1,093 |
| Losartan Potassium | 78 | $1,053 |
| Ezetimibe | 37 | $1,032 |
| Rosuvastatin Calcium | 55 | $787 |
| Carvedilol | 51 | $622 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 29 | $586 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $11,021 | $156,814149 claims |
| NovartisEntresto | $96 | $32,99125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Indianapolis
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Vijay RaoIndianapolis$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
- George LolayIndianapolis$128K
- Onyedika IlonzeIndianapolis$125K
- Noel DasguptaIndianapolis$122K
- Anthony BashallIndianapolis$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.